Editas Medicine |

Editas Medicine is a genome editing firm that research and develops therapies for treating genetic based diseases.

What section would you like to update?
  • Company Logo
  • Company Name & URL
  • Company Description
  • Founded Date
  • Company Status
  • HQ Address
  • Social Links
  • CEO Name & Picture
  • Competitor Set
  • Funding Events
  • Acquisition Events

If you'd like to make any changes to this portfolio we'd be happy to help. Please send info/sources to support@owler.com.


We'll be back up as soon as possible.

Visit owler.uservoice.com for FAQs

Editas Medicine Revenue, Funding, Number of Employees, Competitors and Acquisitions

EDITAS MEDICINE CEO

Katrine S. Bosley

President & CEO

Katrine S. Bosley

Approval Rating: 83/100

WEIGH-IN

How would you rate Katrine S. Bosley as a CEO?

negative
You
neutral
You
positive
You

Founded:

2013

Headquarters:

CambridgeMassachusetts

Status:

PublicNASDAQEDIT

Industry Sector:

Specialty Pharmaceuticals

Completeness:

100%

KEY STATS

Revenue

- -

What is Editas Medicine's revenue?

<1M

Employees

- -

How many people work at Editas Medicine?

Followers on Owler

- -

FOLLOW
UNFOLLOW

TOP COMPETITORS

Add a new competitor:

Thanks for your contribution!

Recalculating The Competitive Graph now...

ADD

Editas Medicine was founded in 2013 and its headquarters is located in Cambridge, Massachusetts, USA. Editas Medicine has $11.0M in revenue and 89 employees. Editas Medicine's top competitors are Illumina, Synthego and CRISPR Therapeutics.

Editas Medicine Competitive Set

COMPANYLEADERSHIPCEO SCORE

EMPLOYEES
(ESTIMATED IF PRIVATE)

TOTAL FUNDING

REVENUE
(ESTIMATED IF PRIVATE)

LIKELY OUTCOME
Editas MedicineEditas Medicine ceo

Katrine S. Bosley

President & CEO

83/100
1Illumina ceoIllumina

Francis deSouza

President & CEO

60/1006,200$96M$14.2B
2Synthego ceoSynthego

Paul Dabrowski

CEO

65/100
$49.7M$3M
3CRISPR Therapeutics ceoCRISPR Therapeutics

Samarth Kulkarni

CEO

95/10022$218M$11M
4Pacific Biosciences of California ceoPacific Biosciences of California

Michael Hunkapiller

Chairman & CEO

51/100438$322.6M$94.3M
5Intellia Therapeutics ceoIntellia Therapeutics

John Leonard

President & CEO

90/10010$193M$24M
6eGenesis ceoeGenesis

Jodie Morrison

President & CEO

90/100
$40M$8.5M
7Toolgen ceoToolgen

Jongmoon Kim

CEO

60/100
$15M
84D Molecular Therapeutics ceo4D Molecular Therapeutics

David Kirn

Co-Founder & CEO

55/100
$21.6M$5M

Editas Medicine Revenue History

company revenue img

Coming soon with Owler Pro!

If you'd like to learn more, please contact us at support@owler.com

$

Community Estimate

UPDATE THIS

Editas Medicine Employee History

company revenue img

Coming soon with Owler Pro!

If you'd like to learn more, please contact us at support@owler.com

Community Estimate

UPDATE THIS

Editas Medicine Leadership

NAMETITLESOCIAL MEDIA
Katrine S. Bosley
Katrine S. Bosley

President & CEO

President & CEO

Editas Medicine Funding History

Since Editas Medicine was founded in 2013, it has participated in 3 rounds of funding. In total Editas Medicine has raised $257.4M. Editas Medicine's last funding round was on Feb 2016 for a total of $94.4M

ROUNDFUNDING DATE AMOUNTINVESTORS
IPOFeb 2016$94.4M
Series BAug 2015$120MDeerfield ManagementViking Global Investors LPFlagship VenturesPolaris PartnersThird Rock Ventures
Series ANov 2013$43MFlagship VenturesPolaris PartnersThird Rock Ventures

Total: $

Editas Medicine News

Editas Medicine: Editas Medicine Names Jessica Hopfield, Ph.D., to Board of DirectorsEditas Medicine Names Jessica Hopfield, Ph.D., to Board of DirectorsCAMBRIDGE, Mass., Feb.PharmiWeb
Editas Medicine: Editas Medicine to Participate in Upcoming Investor ConferencesEditas Medicine to Participate in Upcoming Investor ConferencesCAMBRIDGE, Mass., Feb.PharmiWeb
Editas Medicine: Can CRISPR And These 3 Small Biotechs Cure 10,000 Diseases?Intellia Therapeutics, Crispr Therapeutics and Editas Medicine are at the forefront of the new CRISPR gene editing technology, which could cure thousands of diseases.Investor’s Business Daily
Editas Medicine: Editas, Adverum extend CRISPR ocular delivery allianceEditas Medicine has extended its CRISPR gene editing delivery pact with Adverum Biotechnologies. The amended agreement gives Editas until the end of September to exercise its option on the first of five ocular indications covered by the contract.FierceBiotech
Editas Medicine: Adverum Biotechnologies and Editas Medicine Extend Research CollaborationMENLO PARK, Calif., Jan. 25, 2018 (GLOBE NEWSWIRE) - Adverum Biotechnologies, Inc. (Nasdaq:ADVM), a clinical-stage gene therapy company targeting unmet medical needs in serious rare and ocular diseases, announced today an extension of its collaboration agreement with Editas Medicine, Inc. (Nasdaq:EDIT). The companies established this collaboration to explore the delivery of genome editing medicines to [...]Stock Guru
Editas Medicine: Editas Medicine,Inc. (NASDAQ:EDIT) Files An 8-K Other EventsEditas Medicine,Inc. (NASDAQ:EDIT) Files An 8-K Other EventsItem 8.01. Other Events On January22, 2018, Editas Medicine,Inc. (the "Company") registered for resale 56,099 shares of the Company's common stock, par value $0.0001 per share, to a prospectus supplement under its automatic shelf registration statement on FormS-3 (File No.333-222266), filed with the Securities and Exchange Commission on [...] The post Editas Medicine,Inc. (NASDAQ:EDIT) Files An 8-K Other Events appeared first on Market Exclusive.Market Exclusive
Over the last seven days, Editas Medicine's press coverage more than tripled, up to five mentionsEditas Medicine made the news five times in the past week, including articles in USA TODAY, Benzinga and Zolmax News. This is about five times more than the usual press coverage the company receives. Its top competitor, Intellia Therapeutics, was mentioned only once and close competitor Toolgen was never mentioned.
Editas Medicine: Uh-oh! CRISPR gene-editing stocks may be worthlessA new study suggests that CRISPR may not work in people.USA TODAY
Editas Medicine: Editas Medicine Reports on Recent Progress and Announces "EM22" Five-year Goals at J.P. Morgan Healthcare ConferenceBy the end of 2022, Company expects to have three experimental medicines in early-stage clinical trials and two experimental medicines in or ready for late-stage clinical trialsAnnounces first acquisition with purchase of certain assets from i2 Pharmaceuticals and its affiliates, further strengthening Editas' guide RNA chemistry capabilities and intellectual propertyProvides updates on advancements in ocular and engineered cell medicine programsCAMBRIDGE, Mass., Jan. 08, 2018 (GLOBE NEWSWIRE) -- In a presentation to investors on Wednesday, January 10, 2018, at 8:30 a.m. PST at the 36th Annual J.P. Morgan Healthcare Conference, Editas Medicine, Inc. (NASDAQ:EDIT) President and CEO Katrine Bosley will discuss "EM22," the Company's long-range goals for the year 2022 and vision for advancing Editas Medicine as a leading genome editing company. Ms. Bosley will also outline the Company's acquisition of certain assets and capabilities from i2 Pharmaceuticals and its affiliates (i2 Pharmaceuticals), which further expands the Company's unparalleled gene editing platform, strengthening its guide RNA (gRNA) chemistry capabilities. This is the first acquisition by Editas Medicine.As part of EM22, by year-end 2022 Editas Medicine is driving to deliver on the Company's commitment to make medicines for people with serious diseases around the world by advancing:Three experimental medicines in early-stage clinical trials;Two experimental medicines in or ready for late-stage clinical trials;A best-in-class platform and pipeline for developing genomic medicines; andAll of these achievements fueled by the Company's unique culture.These goals build on Editas Medicine's current success and on the breadth of the Company's platform to make genome editing medicines. The EM22 goals include delivering at least two experimental medicines in ophthalmology and at least one from the collaboration with Juno Therapeutics, Inc., (Juno). Further, the 2022 clinical pipeline is expected to include medicines that incorporate important advancements from the platform as well as at least one new kind of gene edited cell medicine."At Editas Medicine, we have a bold vision for the future. The next five years represents an extraordinary opportunity to harness the power of genome editing, engineered cell therapy, and gene delivery to advance precision genomic ...Full story available on Benzinga.comBenzinga
Editas Medicine: Contrasting Editas Medicine (EDIT) & OptiNose (OPTN)Editas Medicine (NASDAQ: EDIT) and OptiNose (NASDAQ:OPTN) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, analyst recommendations, valuation, institutional ownership, risk, earnings and dividends. Profitability This table compares Editas Medicine and OptiNose's net margins, return on equity and return [...]Zolmax News

SEE MORE

SEE LESS

Editas Medicine Website History

Screengrabs of how the Editas Medicine site has evloved. (Click to expand)

Editas Medicine website history

Jun 2017

Editas Medicine website history

Feb 2017

Editas Medicine website history

Nov 2016

Editas Medicine website history

Aug 2016

Editas Medicine website history

May 2016

Editas Medicine website history

Feb 2016

Editas Medicine website history

Nov 2015

Editas Medicine website history

Aug 2015

Editas Medicine website history

Apr 2015

Editas Medicine website history

Jan 2015

Editas Medicine website history

Sep 2014

Editas Medicine website history

Jun 2014

Owler has collected 12 screenshots of Editas Medicine's website since Jun 2014. The latest Editas Medicine website design screenshot was captured in Jun 2017.

Editas Medicine Headquarters

undefined company logo

11 Hurley St

Cambridge, Massachusetts 02141

617-401-9000

Driving Directions

google map

Editas Medicine Summary Information

Editas Medicine is a genome editing firm that research and develops therapies for treating genetic based diseases. Editas Medicine was founded in 2013. Editas Medicine's headquarters is located in Cambridge, Massachusetts, USA 02141. It has raised 257.4M in 3 rounds. The latest round was in Feb 2016. Some of Editas Medicine's investors include Deerfield Management, Viking Global Investors LP and Flagship Ventures. Editas Medicine's President & CEO, Katrine S. Bosley, currently has an approval rating of 83%. 100% of Owler community believes the stock will go Up. Editas Medicine has 89 employees and reported 11.0M in revenue [trailing four quarters].

Editas Medicine's President & CEO, Katrine S. Bosley, currently has an approval rating of 83%. Editas Medicine's primary competitors are  Illumina Synthego CRISPR Therapeutics.

Visit the Editas Medicine website to learn more.